Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015

GlobalData, the industry analysis specialist’s new report, “Insomnia – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global insomnia market. The report identifies the key trends shaping and driving the global insomnia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global insomnia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The Scope of the report includes
- Annualized global insomnia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include GABA receptor targetters, serotonin receptor targetters, melatonin receptor agonists, histamine receptor antagonists, orexin receptor antagonists.
- Analysis of the current and future market competition in the global insomnia market. Key market players covered are Sanofi Aventis, Somaxon Pharmaceuticals, Vanda Pharmaceuticals Inc., Merck and GlaxoSmithKline.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with insomnia.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global insomnia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global insomnia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global insomnia market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS


1.1 LIST OF TABLES


1.2 LIST OF FIGURES


2 INSOMNIA MARKET: MARKET CHARACTERIZATION

2.1 Overview
2.2 Insomnia Market Size
2.3 Insomnia Market Forecast and CAGR
2.4 Drivers and Barriers for the Insomnia Market
  2.4.1 Drivers for the Insomnia Market
  2.4.2 Barriers for the Insomnia Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 INSOMNIA MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Sales for Major Insomnia Products
3.4 Product Profile for the Major Marketed Products in the Insomnia Market
  3.4.1 Ambien CR (zolpidem tartrate extended-release)
  3.4.2 Lunesta
  3.4.3 Rozerem
3.5 Other Marketed Products for the Insomnia Market
  3.5.1 Zolpimist (zolpidem oral spray)
  3.5.2 Edluar (zolpidem sublingual tablets)
  3.5.3 Circadin (prolonged release melatonin)
3.6 Key Takeaway

4 INSOMNIA MARKET: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Insomnia Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
  4.4.1 Ciltyri (eplivanserin)
  4.4.2 Almorexant
  4.4.3 Silenor (doxepin hydrochloride)
  4.4.4 Tasimelteon (VEC-162)
  4.4.5 Esmirtazapine (ORG 50081)
  4.4.6 Indiplon
4.5 Insomnia Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Insomnia Pipeline – Pipeline by Clinical Phases of Development
  4.6.1 Insomnia Therapeutics – Regulatory and Phase III Clinical Pipeline
  4.6.2 Insomnia Therapeutics – Phase II Clinical Pipeline
  4.6.3 Insomnia Therapeutics – Phase I Clinical Pipeline
  4.6.4 Insomnia Therapeutics – Preclinical Pipeline
  4.6.5 Insomnia Therapeutics – Discovery Pipeline
4.7 Discontinued / Suspended Drugs for Insomnia
4.8 Key Takeaway

5 INSOMNIA MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION


6 INSOMNIA MARKET: FUTURE PLAYERS IN INSOMNIA MARKET

6.1 Introduction
6.2 GlaxoSmithKline
  6.2.1 Overview
  6.2.2 CNS Portfolio
  6.2.3 Insomnia Product Portfolio
6.3 Sanofi Aventis
  6.3.1 Overview
  6.3.2 CNS Portfolio
  6.3.3 Insomnia Product Portfolio
6.4 Somaxon Pharmaceuticals
  6.4.1 Overview
  6.4.2 CNS Portfolio
  6.4.3 Insomnia Product Portfolio
6.5 Vanda Pharmaceuticals Inc.
  6.5.1 Overview
  6.5.2 CNS Portfolio
  6.5.3 Insomnia Product Portfolio
6.6 Merck
  6.6.1 Overview
  6.6.2 CNS Portfolio
  6.6.3 Insomnia Product Portfolio

7 INSOMNIA MARKET: APPENDIX

7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 LIST OF TABLES

Table 1: Global Insomnia Therapeutics Market, Revenue Forecasts, 2000–2008
Table 2: Global Insomnia Therapeutics Market, Revenue Forecasts, 2009–2015
Table 3: Major Marketed Products Comparison in the Insomnia Market, 2009
Table 4: Insomnia Therapeutics – Most Promising Drugs under Clinical Development, 2009
Table 5: Insomnia Therapeutics – Regulatory Filing and Phase III Clinical Pipeline, 2009
Table 6: Insomnia Therapeutics – Phase II Clinical Pipeline, 2009
Table 7: Insomnia Therapeutics – Phase I Clinical Pipeline, 2009
Table 8: Insomnia Therapeutics – Preclinical Pipeline, 2009
Table 9: Insomnia Therapeutics – Discovery Pipeline, 2009

TABLE 10: LIST OF DISCONTINUED DRUGS FOR INSOMNIA, 2009

Table 11: GlaxoSmithKline – CNS Marketed Products, 2009
Table 12: GlaxoSmithKline – CNS Pipeline Products, 2009
Table 13: Sanofi Aventis – CNS Marketed Products, 2009
Table 14: Sanofi Aventis – CNS Pipeline Products, 2009
Table 15: Somaxon Pharmaceuticals – CNS Pipeline Products, 2009
Table 16: Vanda Pharmaceuticals Inc. – CNS Pipeline Products, 2009
Table 17: Merck – CNS Marketed Products, 2009
Table 18: Merck – CNS Pipeline Products, 2009

1.2 LIST OF FIGURES

Figure 1: Global Insomnia Market Forecast 2000–2015
Figure 2: Opportunity and Unmet Need in the Insomnia Market, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products for Insomnia, 2009
Figure 4: Global Sales of Top Insomnia Products, 2009
Figure 5: Technology Trends Analytic Framework of the Insomnia Pipeline, 2009
Figure 6: Technology Trends Analytic Framework of the Insomnia Pipeline - Description, 2009
Figure 7: Insomnia Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2009
Figure 8: Insomnia Pipeline by Phase of Clinical Development, 2009
Figure 9: Implications for Future Market Competition in the Insomnia Market, 2009
Figure 10: Insomnia Therapeutics Market – Clinical Pipeline by Company, 2009
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model
GlaxoSmithKline
Sanofi Aventis
Somaxon Pharmaceuticals
Vanda Pharmaceuticals Inc
Merck
Skip to top